Support

Support Options

Submit a Support Ticket

 

[Illinois] Cancer Community Symposium 2012

See also

No results found.

Category

Workshops

Published on

Abstract

Cancer Community At Illinois Symposium 2012

April 5-6, 2012: Connecting patient care, research, and scientific advancement

Symposium Premise
This on-campus research symposium aims to bring together members of campus and the surrounding community to foster interdisciplinary discussions on cancer research and its affects on patient care. In order to increase understanding and awareness, we will discuss in an open forum with research talks, poster presentations, and panel discussions. We invite community members, clinicians, and researchers from UIUC and other Midwest regional institutions from departments ranging from the social sciences to basic sciences to engineering and medicine.
The symposium features invited talks from nationally-recognized cancer researchers, oral presentations from UIUC faculty and students, and poster sessions. We encourage student researchers from UIUC and from other regional schools to apply (travel awards are available).

About CC@I Symposium
The Cancer Community at Illinois (CC@I) Symposium is organized by a group of students on the University of Illinois campus to bridge the areas of social science, basic sciences to engineering and medicine as they relate to cancer. The symposium mission is to: 1) Facilitate interdisciplinary collaboration and understanding that transcends established departmental affiliation; 2) Foster an increased understanding of the social and environmental factors affecting patients; and 3) Develop unique vantage points afforded by interactive dialogue between and among the various cancer research disciplines. In order to accomplish this, the symposium will engage the local patient community through use of the nascent social and support efforts of the Mills Breast Cancer Institute, Carle Hospital, and regional clinical collaborators.
If you are interested in other CC@I events or the program in general, please contact cancer-community@illinois.edu

Sponsored by

Cite this work

Researchers should cite this work as follows:

  • (2013), "[Illinois] Cancer Community Symposium 2012," http://nanohub.org/resources/17877.

    BibTex | EndNote

Location

University of Illinois, Urbana-Champaign, IL

Submitter

NanoBio Node

University of Illinois at Urbana-Champaign

Tags

In This Workshop

  1. [Illinois] Cancer Community Symposium 2012: Closing Address and Awards

    09 May 2012 | Online Presentations | Contributor(s): Rohit Bhargava

    Jaeyun Sung announces the awards from the poster sessions. Dr. Rohit Bhargava provides the audience with reflections on the conference and thoughts going forward.Cancer Community At Illinois Symposium 2012 April 5-6, 2012: Connecting patient care, research, and scientific advancementSymposium...

  2. [Illinois] Cancer Community Symposium 2012: An Integrated Approach to Cancer Research

    09 May 2012 | Online Presentations | Contributor(s): John F. McDonald

    The field of cancer biology is rapidly moving from an era of specialization to an era of integration. In my presentation, I will provide examples of the integration of molecular biology with analytical chemistry, computer science/machine learning and material science/nanotechnology to develop...

  3. [Illinois] Cancer Community Symposium 2012: Elevated Estrogen Signaling Drives Tumorigenesis in a Novel Animal Model for Ovarian Epithelial Cancer

    09 May 2012 | Online Presentations | Contributor(s): Mary Jo Laws

    We generated a mouse model where aberrant estrogen receptor alpha (Esr1) signaling in the hypothalamo-pituitary-ovarian axis leads to ovarian tumorigenesis. In this model, termed Esr1d/d, the Esr1 gene is selectively deleted in the anterior pituitary. The Esr1d/d mice form palpable ovarian...

  4. [Illinois] Cancer Community Symposium 2012: DriveRank: Discovering Patient-Specific Driver Mutations

    09 May 2012 | Online Presentations | Contributor(s): Jack Pu Hou

    One of the pressing challenges in cancer genomics is to distinguish driver mutations (i.e. mutations involved in tumorigenesis) and passenger mutations (i.e. functionally neutral mutations). Current approaches to identifying driver mutations in cancer look for recurrent events in multiple...

  5. [Illinois] Cancer Community Symposium 2012: Micro-western Arrays for Identification of Novel Mechanisms Underlying Resistance of Cancer Cells to Chemotherapeutic Agents

    09 May 2012 | Online Presentations | Contributor(s): Richard B. Jones

    A fundamental goal in cancer treatment is the delivery of therapeutics in a manner that takes into consideration genetic differences between individuals. Genome-wide association analyses have discovered many DNA variants that influence complex phenotypes such as response to anti-cancer...

  6. [Illinois] Cancer Community Symposium 2012: A Sensitivity Scale for Targeting T Cells with Chimeric Antigen Receptors (CAR) and Bispecific T Cell Engagers (BiTE)

    09 May 2012 | Online Presentations | Contributor(s): Jennifer Stone

    Using a patients immune system to target cancer and maintain long-term surveillance is an attractive goal. Although T cells can respond potently to tumors, immune tolerance mechanisms often result in deletion or inactivation of those T cells expressing specific T cell receptors (TCRs) against...

  7. [Illinois] Cancer Community Symposium 2012: Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB Signaling

    09 May 2012 | Online Presentations | Contributor(s): Elvira de Mejia

    Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB SignalingLunasin is a promising chemopreventive agent. The objective was to study the effect of lunasin on human colon...

  8. [Illinois] Cancer Community Symposium 2012: The Inhibitory Effects of the Antifibrotic Drug Halofuginone on Uterine Leiomyoma Smooth Muscle Cells

    09 May 2012 | Online Presentations | Contributor(s): Faezeh Koohestani

    Uterine leiomyomas are the most prevalent benign tumors of the reproductive tract in women. Available treatments for leiomyomas are limited to surgical procedures or hormonal therapy, which are costly and have significant side effects. In an effort to develop alternative therapeutic strategies,...

  9. [Illinois] Cancer Community Symposium 2012: Understanding and Targeting Transcription in Hematological Malignancies

    09 May 2012 | Online Presentations | Contributor(s): Jonathan D. Licht

    Abnormalities in the epigenetic regulation of chromatin structure and function can lead to aberrant gene expression and cancer development. Epigenetic regulators can be affected by chromosomal rearrangement, point mutations, deletions and amplifications in cancer. The result may be changes in...

  10. [Illinois] Cancer Community Symposium 2012: Panel Discussion

    09 May 2012 | Online Presentations

    Please join us for a panel discussion on the social impact of cancer and how it affects patients, providers, clinicians, and researchers alike. We are fortunate to feature Leslie Hammersmith (moderator), Jennifer Smith, and Patience Anders from the local Young Survival Coalition, as well as an...

  11. [Illinois] Cancer Community Symposium 2012: Chemical Imaging for Histopathology: An Emerging Route for Molecular and Structural Analysis of Tissues

    09 May 2012 | Online Presentations | Contributor(s): Michael Walsh

    Mid-Infrared (IR) spectroscopic imaging is an emerging approach to derive chemical images from tissues based on their inherent biochemistry. Histologic diagnosis is the gold standard for evaluating the presence and severity of most diseases. Current histopathological techniques use of panel of...

  12. [Illinois] Cancer Community Symposium 2012: Materials Science vs. Metastasis

    09 May 2012 | Online Presentations | Contributor(s): Daniel A. Heller

    Metastasis, the spread of cancer cells from a primary tumor to seed secondary tumors in distant sites, is one of the greatest challenges in cancer treatment today. For many patients, by the time cancer is detected, metastasis has already occurred. Over 80% of patients diagnosed with lung cancer,...

  13. [Illinois] Cancer Community Symposium 2012: Speaking Up: The Patient Push for Accelerating Progress in Cancer Research

    09 May 2012 | Online Presentations | Contributor(s): Leslie Hammersmith

    Medical research empowers us to fight cancer, and advocacy empowers us to ensure that it addresses the needs of people affected by cancer. Advocacy helps us get through our cancer experiences, stand up for all people affected by cancer and gain a feeling of control over our own healthcare. Young...

  14. [Illinois] Cancer Community Symposium 2012: The Man with the Crateriform Lesion: Advanced Squamous Cell Carcinoma

    09 May 2012 | Online Presentations | Contributor(s): Joseph Brancheck

    Cutaneous squamous cell carcinoma (SCC) is the second most common type of skin cancer in the United States and accounts for 20 percent of non-melanoma skin cancers; in addition, it is the second most common cancer overall in Caucasians. Due to an aging population and increasing sun exposure, the...

  15. [Illinois] Cancer Community Symposium 2012: Imaging Estrogen Receptors and Estrogen-Receptor Function in Breast Cancer by Positron Emission Tomography (PET): Improved Selection of Patients for Benefit from Endocrine Therapies

    09 May 2012 | Online Presentations | Contributor(s): John A. Katzenellenbogen

    The growth of many breast cancers is regulated by estrogens, and these cancers can be treated effectively with endocrine therapies (ET). Identifying patients who will benefit from ET, however, continues to be challenging. Measurement of estrogen receptor (ER) levels in tumor biopsy samples using...

  16. [Illinois] Cancer Community Symposium 2012: T Cell Receptors For Potential Cancer Immunotherapy Applications: Single Chain T Cell Receptors Circumvent Mispairing with Endogenous TCR and Mediate T Cell Activity

    09 May 2012 | Online Presentations | Contributor(s): David H. Aggen

    To improve the immune response to cancer, gene therapy with tumor-specific T cell-receptors (TCRs) provides an attractive approach to effectively arm patients T cells for tumor cell destruction. A high-affinity TCR specific for an antigenic peptide-major histocompatibility complex (pepMHC) can...

nanoHUB.org, a resource for nanoscience and nanotechnology, is supported by the National Science Foundation and other funding agencies. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.